On the role of sIL-2R measurements in rheumatoid arthritis and cancers

Mediators of Inflammation

Volumn 2005, Issue 3, 2005, Pages 121-130

  Witkowska, Anna Maria ^a  

^a MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; INTERLEUKIN 15 RECEPTOR; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR; INTERLEUKIN 2 RECEPTOR ALPHA; INTERLEUKIN 2 RECEPTOR BETA; INTERLEUKIN 2 RECEPTOR GAMMA; INTERLEUKIN 6; PHOTOSENSITIZING AGENT; TUMOR NECROSIS FACTOR ALPHA;

AMINO ACID SEQUENCE; AUTOIMMUNE DISEASE; BINDING AFFINITY; BREAST CANCER; CANCER; CANCER GROWTH; CARCINOGENESIS; CELL STIMULATION; CELL SURFACE; CELLULAR IMMUNITY; COLORECTAL CANCER; DIETARY INTAKE; DISEASE MARKER; ERYTHROCYTE SEDIMENTATION RATE; ESOPHAGUS CARCINOMA; HEAD AND NECK CANCER; HUMAN; INFLAMMATION; KIDNEY CARCINOMA; LEUKOCYTE ACTIVATION; LUNG ADENOCARCINOMA; LUNG CANCER; LUNG NON SMALL CELL CANCER; LYMPHATIC SYSTEM TUMOR; LYMPHOID CELL LINE; MELANOMA; MOLECULAR WEIGHT; NASOPHARYNX CARCINOMA; NONHUMAN; NUTRITIONAL STATUS; OVARY CANCER; PANCREAS CANCER; PERIPHERAL BLOOD MONONUCLEAR CELL; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DETERMINATION; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROCESSING; PROTEIN STRUCTURE; RECEPTOR BINDING; REVIEW; RHEUMATOID ARTHRITIS; SCLERODERMA; SQUAMOUS CELL CARCINOMA; STANDARD; SYSTEMIC SCLEROSIS; T LYMPHOCYTE ACTIVATION; VASCULITIS;

ARTHRITIS, RHEUMATOID; BIOLOGICAL MARKERS; DISEASE PROGRESSION; HUMANS; MODELS, BIOLOGICAL; NEOPLASMS; RECEPTORS, INTERLEUKIN-2;

EID: 25644435503     PISSN: 09629351     EISSN: 14661861     Source Type: Journal    
DOI: 10.1155/MI.2005.121     Document Type: Review

References (93)

1. Rubin LA, Kurman CC, Fritz ME, et al. Soluble interleukin 2 receptors are released from activated human lymphoid cells in vitro. J Immunol. 1985;135(5):3172-3177.
2. Holter W, Goldman CK, Casabo L, Nelson DL, Green WC, Waldmann TA. Expression of functional IL 2 receptors by lipopolysaccharide and interferon-γ stimulated human monocytes. J Immunol. 1987;138(9):2917-2922.
3. Rand TH, Silberstein DS, Kornfeld H,Weller PF.Human eosinophils express functional interleukin 2 receptors. J Clin Invest. 1991;88(3):825-832.
4. Waldmann TA, Goldman CK, Robb RJ, et al. Expression of interleukin 2 receptors on activated human B cells. J Exp Med. 1984;160(5):1450-1466.
5. Rimoldi D, Salvi S, Hartmann F, et al. Expression of IL-2 receptors in human melanoma cells. Anticancer Res. 1993;13(3):555-564.
6. Weidmann E, Sacchi M, Plaisance S, et al. Receptors for interleukin 2 on human squamous cell carcinoma cell lines and tumor in situ. Cancer Res. 1992;52(21):5963-5970.
7. Yano T, Fukuyama Y, Yokoyama H, et al. Interleukin-2 receptors in pulmonary adenocarcinoma tissue. Lung Cancer. 1996;16(1):13-19.
8. Loughnan MS, Sanderson CJ, Nossal GJV. Soluble interleukin 2 receptors are released from the cell surface of normal murine B lymphocytes stimulated with interleukin 5. Proc Natl Acad Sci U S A. 1988;85(9):3115-3119.
9. Robb RJ, Rusk CM. High and low affinity receptors for interleukin 2: implications of pronase, phorbol ester, and cell membrane studies upon the basis for differential ligand affinities. J Immunol. 1986;137(1):142-149.
10. Sheu BC, Hsu SM, Ho HN, Lien HC, Huang SC, Lin RH. A novel role of metalloproteinase in cancer-mediated immunosuppression. Cancer Res. 2001;61(1):237-242.
11. Rubin LA, Galli F, Greene WC, Nelson DL, Jay G. The molecular basis for the generation of the human soluble interleukin 2 receptor. Cytokine. 1990;2(5):330-336.
12. Bazan JF. Structural design and molecular evolution of a cytokine receptor superfamily. Proc Natl Acad Sci U S A. 1990;87(18):6934-6938.
13. Theze J. Cytokine receptors: a combinative family of molecules. Eur Cytokine Netw. 1994;5(4):353-368.
14. Giri JG, Ahdieh M, Eisenman J, et al. Utilization of the beta and gamma chains of the IL-2 receptor by the novel cytokine IL-15. EMBO J. 1994;13(12):2822-2830.
15. Kondo M, Takeshita T, Ishii N, et al. Sharing of the interleukin-2 (IL-2) receptor gamma chain between receptors for IL-2 and IL-4. Science. 1993;262(5141):1874-1877.
16. Noguchi M, Nakamura Y, Russell SM, et al. Interleukin-2 receptor gamma chain: a functional component of the interleukin-7 receptor. Science. 1993;262(5141):1877-1880.
17. Russell SM, Keegan AD,Harada N, et al. Interleukin-2 receptor gamma chain: a functional component of the interleukin-4 receptor. Science. 1993;262(5141):1880-1883.
18. Honda M, Kitamura K, Takeshita T, Sugamura K, Tokunaga T. Identification of a soluble IL-2 receptor beta-chain from human lymphoid cell line cells. J Immunol. 1990;145(12):4131-4135.
19. Nielsen OH, Ciardelli T, Wu Z, Langholz E, Kirman I. Circulating soluble interleukin-2 receptor alpha and beta chain in inflammatory bowel disease. Am J Gastroenterol. 1995;90(8):1301-1306.
20. Nielsen OH, Kirman I, Johnson K, Giedlin M, Ciardelli T. The circulating common gamma chain (CD132) in inflammatory bowel disease. Am J Gastroenterol. 1998;93(3):323-328.
21. Nishio J, Kohsaka H, Shimamura T, Hamuro J, Miyasaka N. Abundant expression of common cytokine receptor gamma chain (CD132) in rheumatoid joints. J Rheumatol. 2001;28(2):240-244.
22. c) in activated human lymphocyte cultures-comparison with soluble IL-2R α. Immunol Lett. 2002;82(3):235-240.
23. Eicher DM, Damjanovich S, Waldmann TA. Oligomerization of IL-2R alpha. Cytokine. 2002;17(2):82-90.
24. Greene WC, Robb RJ, Svetlik PB, Rusk CM, Depper JM, Leonard WJ. Stable expression of cDNA encoding the human interleukin 2 receptor in eukaryotic cells. J Exp Med. 1985;162(1):363-368.
25. Leonard WJ, Depper JM, Crabtree GR, et al. Molecular cloning and expression of cDNAs for the human interleukin-2 receptor. Nature. 1984;311(5987):626-631.
26. Robb RJ, Rusk CM, Neeper MP. Structure-function relationships for the interleukin 2 receptor: location of ligand and antibody binding sites on the Tac receptor chain by mutational analysis. Proc Natl Acad Sci U S A. 1988;85(15):5654-5658.
27. Minami Y, Kono T, Yamada K, Taniguchi T. The interleukin-2 receptors: insights into a complex signalling mechanism. Biochim Biophys Acta. 1992;1114(2-3):163-177.
28. Gotoh Y, Okamoto Y, Uemura O, et al. Determination of age-related changes in human soluble interleukin 2 receptor in body fluids of normal subjects as a control value against disease states. Clin Chim Acta. 1999;289(1-2):89-97.
29. Gilad R, Lampl Y, Eshel Y, Barak V, Sarova-Pinhas I. Cerebrospinal fluid soluble interleukin-2 receptor in cerebral lupus. Br J Rheumatol. 1997;36(2):190-193.
30. Rubin LA, Jay G, Nelson DL. The released interleukin 2 receptor binds interleukin 2 efficiently. J Immunol. 1986;137(12):3841-3844.
31. Gooding R, Riches P, Dadian G, Moore J, Gore M. Increased soluble interleukin-2 receptor concentration in plasma predicts a decreased cellular response to IL-2. Br J Cancer. 1995;72(2):452-455.
32. Sack U, Burkhardt U, Borte M, Schädlich H, Berg K, Emmrich F. Age-dependent levels of select immunologicalmediators in sera of healthy children. Clin Diagn Lab Immunol. 1998;5(1):28-32.
33. Bruunsgaard H, Pedersen AN, Schroll M, Skinhoj P, Pedersen BK. TNF-α, leptin, and lymphocyte function in human aging. Life Sci. 2000;67(22):2721-2731.
34. Rubin LA, Nelson DL. The soluble interleukin-2 receptor: biology, function, and clinical application. Ann Intern Med. 1990;113(8):619-627.
35. Nagata T, Kiriike N, Tobitani W, Kawarada Y, Matsunaga H, Yamagami S. Lymphocyte subset, lymphocyte proliferative response, and soluble interleukin-2 receptor in anorexic patients. Biol Psychiatry. 1999;45(4):471-474.
36. Allende LM, Corell A, Manzanares J, et al. Immunodeficiency associated with anorexia nervosa is secondary and improves after refeeding. Immunology. 1998;94(4):543-551.
37. Haack M, Pollmächer T, Mullington JM. Diurnal and sleep-wake dependent variations of soluble TNF- and IL-2 receptors in healthy volunteers. Brain Behav Immun. 2004;18(4):361-367.
38. Asano M, Toda M, Sakaguchi N, Sakaguchi S. Autoimmune disease as a consequence of developmental abnormality of a T cell subpopulation. J Exp Med. 1996;184(2):387-396.
39. + T cells. Eur J Immunol. 1995;25(11):3053-3059.
40. Suzuki H, Kundig TM, Furlonger C, et al. Deregulated T cell activation and autoimmunity in mice lacking interleukin-2 receptor beta. Science. 1995;268(5216):1472-1476.
41. Klebb G, Autenrieth IB, Haber H, et al. Interleukin-2 is indispensable for development of immunological self-tolerance. Clin Immunol Immunopathol. 1996;81(3):282-286.
42. Nassonov EL, Samsonov MY, Chichasova NV, et al. Soluble adhesion molecules in rheumatoid arthritis. Rheumatology (Oxford). 2000;39(7):808-810.
43. Ribbens C, Andre B, Kaye O, et al. Increased synovial fluid levels of interleukin-12, sCD25 and sTNFRII/ sTNF-RI ratio delineate a cytokine pattern characteristic of immune arthropathies. Eur Cytokine Netw. 2000;11(4):669-676.
44. Tebib JG, Letroublon MC, Noel E, Bienvenu J, Bouvier M. sIL-2R levels in rheumatoid arthritis: poor correlation with clinical activity is due in part to disease duration. Br J Rheumatol. 1995;34(11):1037-1040.
45. Symons JA,Wood NC, Di Giovine FS, Duff GW. Soluble IL-2 receptor in rheumatoid arthritis. Correlation with disease activity, IL-1 and IL-2 inhibition. J Immunol. 1988;141(8):2612-2618.
46. Itoh M, Goto Y, Ohta Y, Goto Y, Ohashi H. Relations between surface expression of the interleukin-2 receptor and release of the soluble form of the receptor in cultured mononuclear cells from patients with rheumatoid arthritis or systemic lupus erythematosus. Clin Rheumatol. 1998;17(1):26-30.
47. Rubin LA, Snow KM, Kurman CC, Nelson DL, Keystone EC. Serial levels of soluble interleukin 2 receptor in the peripheral blood of patients with rheumatoid arthritis: correlations with disease activity. J Rheumatol. 1990;17(5):597-602.
48. Klimiuk PA, Sierakowski S, Latosiewicz R, et al. Interleukin-6, soluble interleukin-2 receptor and soluble interleukin-6 receptor in the sera of patients with different histological patterns of rheumatoid synovitis. Clin Exp Rheumatol. 2003;21(1):63-69.
49. Fröde TS, Tenconi P, Debiasi MR, Medeiros YS. Tumor necrosis factor-alpha, interleukin-2 soluble receptor and different inflammatory parameters in patients with rheumatoid arthritis.Mediators Inflamm. 2002;11(6):345-349.
50. Symons JA,McDowell TL, di Giovine FS,Wood NC, Capper SJ, Duff GW. Interleukin 1 in rheumatoid arthritis: potentiation of immune responses within the joint. Lymphokine Res. 1989;8(3):365-372.
51. Stockenhuber F, Keil M, Wurnig C, Kurz RW, Gottsauner-Wolf M, Balcke P. Impaired erythropoietin responsiveness in anaemic rheumatoid arthritis patients: potential relation to immune mechanisms. Clin Sci (Lond). 1994;86(5):633-638.
52. Oelzner P, Franke S,Müller A, Hein G, Stein G. Relationship between soluble markers of immune activation and bone turnover in post-menopausal women with rheumatoid arthritis. Rheumatology (Oxford). 1999;38(9):841-847.
53. Wood NC, Symons JA, Duff GW. Serum interleukin-2-receptor in rheumatoid arthritis: a prognostic indicator of disease activity? J Autoimmun. 1988;1(4):353-361.
54. Franke S, Herrmann D, Hein G, Muller A, Stein G. Interleukin-6, soluble interleukin-2-receptor and soluble interleukin-6-receptor in sera of patients with rheumatoid arthritis: influences of disease activity and drug therapy. Eur J Med Res. 1997;29(9):401-406.
55. Pollison RP, Dooley MA, Dawson DV, Pisetsky DS. Interleukin-2 receptor levels in the sera of rheumatoid arthritis patients treated with methotrexate. Arthritis Rheum. 1994;37(1):50-56.
56. Boiardi L, Macchioni P, Salvarani C, et al. Serum soluble interleukin-2 receptor levels in rheumatoid arthritis: correlation with clinical and immunological parameters and with the response to auranofin treatment. Clin Exp Rheumatol. 1994;12(4):357-362.
57. Mangge H, Gallistl S, Schauenstein K. Long-term follow-up of cytokines and soluble cytokine receptors in peripheral blood of patients with juvenile rheumatoid arthritis. J Interferon Cytokine Res. 1999;19(9):1005-1010.
58. Suenaga Y, Yasuda M, Yamamoto M, et al. Serum interleukin-2 receptor for the early diagnosis of rheumatoid arthritis. Clin Rheumatol. 1998;17(4):311-317.
59. Lissoni P, Barni S, Rovelli F, et al. The biological significance of soluble interleukin-2 receptors in solid tumors. Eur J Cancer. 1990;26(1):33-36.
60. Wasik MA, Sioutos N, Tuttle M, Butmarc JR, Kaplan WD, Kadin ME. Constitutive secretion of soluble interleukin-2 receptor by human T cell lymphoma xenografted into SCID mice. Correlation of tumor volume with concentration of tumor-derived soluble interleukin-2 receptor in body fluids of the host mice. Am J Pathol. 1994;144(5):1089-1097.
61. Boyano MD, Garcia-Vasquez MD, Lopez-Michelena T, et al. Soluble interleukin-2 receptor, intercellular adhesion molecule-1 and interleukin-10 serum levels in patients with melanoma. Br J Cancer. 2000;83(7):847-852.
62. Vuoristo MS, Laine S, Huhtala H, et al. Serum adhesion molecules and interleukin-2 receptor as markers of tumor load and prognosis in advanced cutaneous melanoma. Eur J Cancer. 2001;37(13):1629-1634.
63. Ostenstad B. Soluble interleukin-2 receptor levels in patients with malignant melanoma and renal cell cancer. Acta Oncol. 1992;31(4):413-415.
64. Tsai MH, Chiou SH, Chow KC. Effect of platelet activating factor and butyrate on the expression of interleukin-2 receptor a in nasopharyngeal carcinoma cells. Int J Oncol. 2001;19(5):1049-1055.
65. Witkowska A, Borawska M, Łuczaj J, Chodynicki S. The influence of dietary habits on soluble interleukin 2 receptor (SIL-2R) in the serum of subjects with head and neck cancers: a preliminary study. Bromat Chem Toksykol. 2003;34:187-190.
66. Lai KN, Ho S, Leung JC, Tsao SY. Soluble interleukin-2 receptors in patients with nasopharyngeal carcinoma. Cancer. 1991;67(8):2180-2185.
67. Tartour E, Mosseri V, Jouffroy T, et al. Serum soluble interleukin-2 receptor concentrations as an independent prognostic marker in head and neck cancer. Lancet. 2001;357(9264):1263-1264.
68. Lai JP, Tao ZD, Xiao JY, Zhao SP, Tian YQ. Effect of photodynamic therapy on selected laboratory values of patients with nasopharyngeal carcinoma. Ann Otol Rhinol Laryngol. 1997;106(8):680-682.
69. Yano T, Yoshino I, Yokoyama H, et al. The clinical significance of serum soluble interleukin-2 receptors in lung cancer. Lung Cancer. 1996;15(1):79-84.
70. Aleman MR, Santolaria F, Batista N, et al. Leptin role in advanced lung cancer. A mediator of the acute phase response or a marker of the status of nutrition? Cytokine. 2002;19(1):21-26.
71. Kawashima O, Kamiyoshihara M, Sakata S, Endo K, Saito R, Morishita Y. The clinicopathological significance of preoperative serum-soluble interleukin-2 receptor concentrations in operable non-small-cell lung cancer patients. Ann Surg Oncol. 2000;7(3):239-245.
72. Tisi E, Lissoni P, Angeli M, et al. Postoperative increase in soluble interleukin-2 receptor serum levels as predictor for early recurrence in non-small cell lung carcinoma. Cancer. 1992;69(10):2458-2462.
73. Brunetti G, Bossi A, Baiardi P, et al. Soluble interleukin 2 receptor (sIL2R) in monitoring advanced lung cancer during chemotherapy. Lung Cancer. 1999;23(1):1-9.
74. Abbate I, Correale M, Gargano G, et al. Tumor necrosis factor and soluble interleukin-2 receptor: two immunological biomarkers in female neoplasms. Eur J Gynaecol Oncol. 1992;13(suppl 1):92-96.
75. Sharma S, Saha K, Shingal RN,Malik GB. Serum soluble interleukin-2 (IL-2) receptor levels in women with breast carcinoma and its correlation with IL-2 receptor expression on blood lymphocytes and lymphocytic infiltration within the tumor. Cancer Immunol Immunother. 1991;33(3):198-202.
76. Tesarova P, Kvasnicka J, Umlaufova A, Homolkova H, Jirsa M, Tesar V. Soluble TNF and IL-2 receptors in patients with breast cancer. Med Sci Monit. 2000;6(4):661-667.
77. Klein B, Levin I, Kfir B, Mishaeli M, Shapira J, Klein T. The significance of soluble interleukin-2, soluble interleukin-2 receptors, soluble ICAM-1 and β 2-microglobulin in breast cancer patients. Tumour Biol. 1995;16(5):290-296.
78. Sabbioni MEE, Siegrist HP, Bacchi M, et al. Association between immunity and prognostic factors in early stage breast cancer patients before adjuvant treatment. Breast Cancer Res Treat. 2000;59(3):279-287.
79. Maccio A, Lai P, Santona MC, Pagliara L, Melis GB, Mantovani G. High serum levels of soluble IL-2 receptor, cytokines, and C reactive protein correlate with impairment of T cell response in patients with advanced epithelial ovarian cancer. Gynecol Oncol. 1998;69(3):248-252.
80. Barton DP, Blanchard DK, Michelini-Norris B, Nicosia SV, Cavanagh D, Djeu JY. High serum and ascitic soluble interleukin-2 receptor a levels in advanced epithelial ovarian cancer. Blood. 1993;81(2):424-429.
81. Böhm M, Ittenson A, Schierbaum KF, Röhl FW, Ansorge S, Allhoff EP. Pretreatment with interleukin-2 modulates peri-operative immuno-dysfunction in patients with renal cell carcinoma. Eur Urol. 2002;41(4): 458-468.
82. Gansauge F, Steinbach G, Gansauge S, et al. Prognostic significance of soluble interleukin-2 receptor-a in adenocarcinoma of the pancreas. Cancer Lett. 1998;134(2):193-199.
83. Saito H, Tsujitani S, Katano K, Ikeguchi M, Maeta M, Kaibara N. Levels of serum-soluble receptor for interleukin-2 in patients with colorectal cancer. Surg Today. 1998;28(10):1115-1117.
84. Gansauge S, Gansauge F, Negri G, et al. The role of anti-p53- autoantibodies in pancreatic disorders. Int J Pancreatol. 1996;19(3):171-178.
85. Matsumoto T, Furukawa A, Sumiyoshi Y, Akiyama KY, Kanayama HO, Kagawa S. Serum levels of soluble interleukin-2 receptor in renal cell carcinoma. Urology. 1998;51(1):145-149.
86. Wang LS, Chow KC, Li WY, Liu CC, Wu YC, Huang MH. Clinical significance of serum soluble interleukin 2 receptor-α in esophageal squamous cell carcinoma. Clin Cancer Res. 2000;6(4):1445-1451.
87. Sakata H, Murakami S, Hirayama R. Serum soluble interleukin-2 receptor (IL-2R) and immunohistochemical staining of IL-2R/Tac antigen in colorectal cancer. Int J Clin Oncol. 2002;7(5):312-317.
88. Lee GL, Chen MY, Chuang CY, Chen CY. Serum interleukin-2 receptor in systemic lupus erythematosus and rheumatoid arthritis. Zhonghua Min Guo Wei Sheng Wu Ji Mian Yi Xue Za Zhi. 1988;21(1):16-22.
89. Pountain G, Hazleman B, Cawston TE. Circulating levels of IL-1 β, IL-6 and soluble IL-2 receptor in polymyalgia rheumatica and giant cell arteritis and rheumatoid arthritis. Br J Rheumatol. 1998;37(7):797-798.
90. Arranz O, Ara J, Rodriguez R, Saurina A,Mirapeix E, Darnell A. Serum levels of soluble interleukin-2 receptor in patients with ANCA-associated vasculitis. J Nephrol. 2000;13(1):59-64.
91. Lis AD, Brzezińska-Wcisło LA. Soluble receptors of cytokines in sera of patients with systemic sclerosis - clinical correlation. Wiad Lek. 2003;56(11-12):532-536.
92. Søndergaard K, Stengaard-Pedersen K, Zachariae H, Heickendorff L, Deleuran M, Deleuran B. Soluble intercellular adhesion molecule-1 (sICAM-1) and soluble interleukin-2 receptors (sIL-2R) in scleroderma skin. Br J Rheumatol. 1998;37(3):304-310.
93. Chibowska M, Krasowska D, Weglarz J. Pentoxifilline treatment does not influence the plasma levels of IL-2 and sIL-2R in limited scleroderma patients. Med Sci Monit. 2001;7(2):282-288.